• Phil Lieberman
Part of the Current Clinical Practice book series (CCP)


The term, “anaphylaxis” refers to a systemic, immediate hypersensitivity reaction resulting from IgE-mediated mast cell and/or basophil degranulation. This degranulation releases chemicals responsible for the clinical event. The term, “anaphylactoid reaction” refers to a clinically similar occurrence not mediated by IgE.


Mast Cell Hydroxyethyl Starch Anaphylactoid Reaction Systemic Mastocytosis Monosodium Glutamate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Blaiss M. Anaphylaxis In: Current Practice of Medicine, Churchill Livingstone (Roger Bone, series editor), 1996.Google Scholar
  2. Lieberman P. Specific and Idiopathic Anaphylaxis: Pathophysiology and Treatment. Allergy, Asthma and Immunology from Infancy to Adulthood-3rd ed. Bierman W, Parlman D, Sharpiro G, Busse W. eds., W. B. Saunders, pp. 297–320, 1996.Google Scholar
  3. Lieberman P. Distinguishing anaphylaxis from other serious disorders. J Respir Dis 1995; 16 (4): 411–420.Google Scholar
  4. Lieberman P. Anaphylaxis: guidelines for prevention and management. J Respir Dis 1995; 16 (5): 456–462.Google Scholar
  5. Winbery SL and Lieberman P. Anaphylaxis and histamine antagonists in: Histamine and H1 Receptor Antagonists in Allergic Disease, Clinical Allergy and Immunology, F. Estelle R. Simons (ed.). Marcel Dekker, Inc., vol. 7:297–327, 1996.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Phil Lieberman

There are no affiliations available

Personalised recommendations